SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?


To: Sean Collett who wrote (78168)9/30/2025 8:49:00 PM
From: E_K_S  Read Replies (1) | Respond to of 78476
 
I wonder if BRK's OXY Preferred is/will be part of the payment; a swap of assets

Berkshire Hathaway (BRK) initially invested $10 billion in Occidental Petroleum's (OXY) 8% Cumulative Perpetual Preferred Stock in 2019 to help finance OXY's acquisition of Anadarko.

The key points on the value and redemptions are:
  • Initial Liquidation Value: $10 billion (100,000 shares with a $100,000 liquidation value per share).

  • Dividend: The preferred stock pays an 8% annual dividend, or $800 million per year.

  • Current Value: Occidental has made mandatory redemptions, primarily based on the amount of cash returned to common shareholders above a certain threshold.

    • As of March 31, 2024, the aggregate liquidation value of BRK's preferred stock investment was approximately $8.5 billion, reflecting mandatory redemptions of about $1.5 billion during 2023. This value changes as more redemptions occur.

Regarding the rumored purchase of OxyChem:

  • The speculation is that Berkshire Hathaway may be in talks to acquire Occidental Petroleum's petrochemical division, OxyChem, for an estimated $10 billion.

  • Media reports indicate this would be a separate, outright acquisition by Berkshire.

  • There is no confirmed information that the existing OXY preferred stock would be directly used as currency for the OxyChem purchase. The preferred stock is a debt-like instrument that OXY is paying off, and an acquisition would typically be a new transaction.

  • However, if such a deal were to close, the $10 billion cash proceeds from the sale of OxyChem would significantly help Occidental accelerate its debt reduction efforts, which would likely include redeeming the remainder of Berkshire Hathaway's preferred stock as it is a high-cost financing source for OXY.